Drug Profile
Oral therapeutic - IntelGenx/Par Pharmaceutical
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator IntelGenx Corp.; Par Pharmaceutical Inc
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Undefined in Canada (PO)
- 05 Nov 2015 Par Pharmaceutical Inc has been acquired by Endo International
- 31 Mar 2012 Clinical trials in Undefined indication in Canada (PO)